Understanding Her2 Er Breast Cancer Neoadjuvant Therapy Options
Let's dive into the details surrounding Her2 Er Breast Cancer Neoadjuvant Therapy Options. Hope S. Rugo, MD, discusses the
Key Takeaways about Her2 Er Breast Cancer Neoadjuvant Therapy Options
- In discussion with Dr. Harold Burstein, we cover
- Sherene Loi, MD, PhD, PeterMacCallum
- Debu Tripathy, MD, chair of
- Virginia Kaklamani, MD, UT Southwestern Medical Center, Dallas, TX, talks on the predictive value of
- This video is part of the HMP Education content archive and may include previously accredited educational material. While this ...
Detailed Analysis of Her2 Er Breast Cancer Neoadjuvant Therapy Options
Cynthia X. Ma, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, discusses the results of the ... The rationale behind Sara M. Tolaney, MD, MPH, describes the rationale for preoperative
Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of ...
That wraps up our extensive overview of Her2 Er Breast Cancer Neoadjuvant Therapy Options.
